Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Fosbretabulin

Generic Name: Fosbretabulin

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₁O_₈P

CAS Number: 222030-63-9

Unique Ingredient Identifier: I5590ES2QZ

Overview

Fosbretabulin has been investigated for the treatment of Anaplastic Thyroid Cancer.

Background

Fosbretabulin has been investigated for the treatment of Anaplastic Thyroid Cancer.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer

Phase 3

Withdrawn

Posted: 2012/10/05

Sponsor:

Mateon Therapeutics

ID:NCT01701349

Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration

Phase 1

Completed

Posted: 2012/04/04

Sponsor:Johns Hopkins Univer...

ID:NCT01570790

Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia

Phase 2

Completed

Posted: 2011/08/25

Sponsor:

Mateon Therapeutics

ID:NCT01423149

Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Phase 2

Completed

Posted: 2011/02/28

Sponsor:National Cancer Inst...

ID:NCT01305213

Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV)

Phase 2

Completed

Posted: 2009/12/02

Sponsor:

Mateon Therapeutics

ID:NCT01023295

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy